\n| Unsure if you qualify<\/td>\n | Medical evaluation first<\/td>\n | BMI, labs, contraindications, and health history all matter<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\nGLP-1 Medications for Weight Loss: Full Comparison<\/h2>\nTirzepatide and semaglutide carry the strongest weight-loss data. They are the two medications most patients compare when choosing an injection for weight loss.<\/p>\n \n\n\n| Medication<\/th>\n | Brand names<\/th>\n | How taken<\/th>\n | Avg. weight loss<\/th>\n | Primary use<\/th>\n<\/tr>\n<\/thead>\n | \n\n| Tirzepatide<\/td>\n | Zepbound, Mounjaro<\/td>\n | Weekly injection<\/td>\n | ~18\u201322%<\/td>\n | Weight management \/ T2D<\/td>\n<\/tr>\n | \n| Semaglutide<\/td>\n | Wegovy, Ozempic, Rybelsus<\/td>\n | Weekly injection or oral<\/td>\n | ~15\u201317%<\/td>\n | Weight management \/ T2D<\/td>\n<\/tr>\n | \n| Liraglutide<\/td>\n | Saxenda, Victoza<\/td>\n | Daily injection<\/td>\n | ~8\u201310%<\/td>\n | Weight management \/ T2D<\/td>\n<\/tr>\n | \n| Dulaglutide<\/td>\n | Trulicity<\/td>\n | Weekly injection<\/td>\n | ~5\u20137%<\/td>\n | Type 2 diabetes only<\/td>\n<\/tr>\n | \n| Exenatide<\/td>\n | Byetta, Bydureon<\/td>\n | Daily or weekly injection<\/td>\n | ~5\u201310%<\/td>\n | Type 2 diabetes only<\/td>\n<\/tr>\n | \n| Retatrutide<\/td>\n | Emerging (trials)<\/td>\n | Weekly injection (pending)<\/td>\n | ~20\u201330% (early trials)<\/td>\n | In development<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n Note: Tirzepatide is often grouped with GLP-1 medications, but it is technically a dual GIP\/GLP-1 receptor agonist not a pure GLP-1 drug. This dual mechanism is likely responsible for its stronger average weight-loss results compared to semaglutide.<\/p>\n Tirzepatide vs. Semaglutide: Which Is Better for Weight Loss?<\/h3>\nBoth medications reduce appetite, increase satiety, slow stomach emptying, and may improve blood sugar control. Both are weekly injections. Both require a prescription and medical supervision. But they work differently, and those differences matter.<\/p>\n Tirzepatide is the active ingredient in Zepbound and Mounjaro. It activates both the GIP receptor and the GLP-1 receptor simultaneously. This dual action appears to amplify appetite suppression and metabolic regulation beyond what GLP-1 activation alone produces, which is why clinical trials consistently show greater average weight loss with tirzepatide.<\/p>\n Semaglutide is the active ingredient in Wegovy, Ozempic, and Rybelsus. It activates the GLP-1 receptor and has the strongest long-term safety and cardiovascular outcome data of any GLP-1 medication currently available. The STEP 1 trial (Wilding et al., The Lancet, 2021) showed an average weight loss of 14.9% over 68 weeks versus 2.4% in the placebo group a landmark result that established semaglutide as the benchmark for GLP-1 weight loss.<\/p>\n For average weight loss, tirzepatide leads. But semaglutide may be the better clinical choice for patients with cardiovascular disease, those whose insurance covers it more favorably, or those whose providers have more experience managing it. The final decision should always follow a complete medical review.<\/p>\n Zepbound vs. Wegovy, Ozempic vs. Mounjaro: What Is the Difference?<\/h3>\nThe same active ingredient is often sold under two brand names one for diabetes management and one for weight management. This affects insurance coverage, approved dosing, and how your provider writes the prescription.<\/p>\n Zepbound vs. Wegovy, Ozempic vs. Mounjaro: Brand Differences<\/h2>\n\n\n\n| Brand<\/th>\n | Active ingredient<\/th>\n | Primary approval<\/th>\n | Dosing<\/th>\n<\/tr>\n<\/thead>\n | \n\n| Zepbound<\/td>\n | Tirzepatide<\/td>\n | Chronic weight management<\/td>\n | Weekly injection<\/td>\n<\/tr>\n | \n| Mounjaro<\/td>\n | Tirzepatide<\/td>\n | Type 2 diabetes<\/td>\n | Weekly injection<\/td>\n<\/tr>\n | \n| Wegovy<\/td>\n | Semaglutide<\/td>\n | Chronic weight management<\/td>\n | Weekly injection<\/td>\n<\/tr>\n | \n| Ozempic<\/td>\n | Semaglutide<\/td>\n | Type 2 diabetes<\/td>\n | Weekly injection<\/td>\n<\/tr>\n | \n| Rybelsus<\/td>\n | Semaglutide<\/td>\n | Type 2 diabetes<\/td>\n | Daily oral tablet<\/td>\n<\/tr>\n | \n| Saxenda<\/td>\n | Liraglutide<\/td>\n | Chronic weight management<\/td>\n | Daily injection<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n If your primary goal is weight loss, Zepbound and Wegovy are the most directly relevant brands. Mounjaro and Ozempic may still be prescribed off-label for weight management in certain cases, but insurance coverage for obesity treatment is tied to the weight-management-approved brands.<\/p>\n Is GLP-1 Weight Loss Permanent?<\/h3>\nGLP-1 medications produce lasting results only when combined with sustainable lifestyle changes. Clinical data shows that patients who stop taking these medications without a maintenance plan in place regain an average of two-thirds of lost weight within a year.<\/p>\n This does not mean lifelong medication is required. Many patients use GLP-1 therapy as a structured period 12 to 24 months to reset appetite patterns, establish healthier habits, and reach a weight their body can maintain. Others choose a long-term maintenance dose, which is increasingly common and clinically supported.<\/p>\n At our NYC practice, the goal is never dependence on a drug. It is using the medication window strategically to build the foundation that makes results last.<\/p>\n How Much Weight Can You Lose With GLP-1 Medication?<\/h2>\nWeight loss depends on the medication, the dose, consistency, metabolism, nutrition, activity, and how closely follow-up care is maintained. The timeline below reflects what most patients experience on a well-supervised plan.<\/p>\n GLP-1 Weight Loss Timeline<\/h2>\n\n\n\n| Timeline<\/th>\n | What happens<\/th>\n<\/tr>\n<\/thead>\n | \n\n| Weeks 1\u20134<\/td>\n | Appetite decreases. Fullness arrives sooner. Nausea or constipation may occur as the body adjusts.<\/td>\n<\/tr>\n | \n| Months 2\u20133<\/td>\n | Dose increases continue. Weight loss becomes more visible. Side effects improve.<\/td>\n<\/tr>\n | \n| Months 3\u20136<\/td>\n | Stronger changes in weight, waist size, cravings, and appetite. Most patients reach their optimal dose.<\/td>\n<\/tr>\n | \n| Months 6\u201312+<\/td>\n | Continued loss requires consistency. A maintenance plan should begin taking shape.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\nHow fast does GLP-1 weight loss start?<\/h3>\nAppetite changes may begin in the first one to four weeks. Meaningful weight loss becomes visible around months two to three, as the dose increases. Larger results build over six to twelve months.<\/p>\n How to Choose the Right GLP-1 for You<\/h2>\nChoosing a GLP-1 medication is not about picking the one with the highest average result. It is about matching a medication to your health profile, your goals, and your ability to stay on it long-term. Here are the factors that matter most.<\/p>\n Weight-Loss Goal<\/strong><\/p>\nFor maximum average loss, tirzepatide leads. For strong, proven results with more insurance support, semaglutide is the standard.<\/p>\n Existing Health Conditions<\/strong><\/p>\nType 2 diabetes, PCOS, insulin resistance, and cardiovascular disease all influence which medication a provider may prefer.<\/p>\n Budget and Insurance<\/strong><\/p>\nBrand-name GLP-1 medications can exceed $1,000\/month without coverage. Manufacturer savings programs can reduce semaglutide to $149\u2013$299\/month for eligible patients.<\/p>\n Side-Effect Tolerance<\/strong><\/p>\nGI side effects nausea, constipation, vomiting are common early on. Slower dose titration reduces severity for most patients.<\/p>\n Injection Preference<\/strong><\/p>\nWeekly injections are available for both tirzepatide and semaglutide. Oral semaglutide (Rybelsus) exists but is lower efficacy and approved only for type 2 diabetes.<\/p>\n Cardiovascular History<\/strong><\/p>\nSemaglutide has the strongest cardiovascular outcomes data. It may be the preferred choice for patients with established CV disease.<\/p>\n Best GLP-1 Based on Your Situation<\/h2>\n\n\n\n| Your situation<\/th>\n | Likely best option<\/th>\n | Reason<\/th>\n<\/tr>\n<\/thead>\n | \n\n| Maximum weight loss is the priority<\/td>\n | Zepbound (tirzepatide)<\/td>\n | Highest average weight-loss data in clinical trials<\/td>\n<\/tr>\n | \n| Strong GLP-1 with broad coverage<\/td>\n | Wegovy (semaglutide)<\/td>\n | Proven results, strongest CV outcome data, wide insurance coverage<\/td>\n<\/tr>\n | \n| Type 2 diabetes + weight loss<\/td>\n | Ozempic or Mounjaro (discuss with provider)<\/td>\n | Diabetes-approved brands; coverage often stronger<\/td>\n<\/tr>\n | \n| Prefer no injections<\/td>\n | Rybelsus (oral semaglutide)<\/td>\n | Lower efficacy; approved for T2D, not obesity label<\/td>\n<\/tr>\n | \n| Cost is a major concern<\/td>\n | Semaglutide with manufacturer discount<\/td>\n | Discount programs can reduce to ~$149\u2013$299\/month<\/td>\n<\/tr>\n | \n| History of cardiovascular disease<\/td>\n | Semaglutide<\/td>\n | SELECT trial showed 20% reduction in CV events<\/td>\n<\/tr>\n | \n| Earlier in weight-loss journey, lower BMI<\/td>\n | Saxenda (liraglutide)<\/td>\n | Moderate results; may suit patients not yet at tirzepatide threshold<\/td>\n<\/tr>\n | \n| Unsure about eligibility<\/td>\n | Medical evaluation<\/td>\n | BMI, labs, and health history determine safe options<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\nHow GLP-1 Medications Produce Weight Loss<\/h2>\nGLP-1 medications change the hormonal signals that control hunger and fullness. When you eat, GLP-1 is naturally released from your gut these medications mimic that hormone at sustained, higher concentrations. The result is a meaningful reduction in calorie intake that does not depend on willpower alone.<\/p>\n The four primary mechanisms are: signaling the hypothalamus to suppress hunger, slowing gastric emptying so fullness lasts longer, stimulating insulin release after meals to prevent blood sugar spikes, and suppressing glucagon to reduce glucose release from the liver. Tirzepatide adds GIP receptor activation to this process, which is why its appetite-suppressing effect tends to be stronger.<\/p>\n What Are The Side Effects of GLP-1 Medications<\/h2>\nGLP-1 medications are generally well tolerated. Most side effects are gastrointestinal and occur during the early weeks of treatment or when the dose is increased. They improve significantly for most patients as the body adjusts.<\/p>\n Common side effects<\/strong><\/p>\n | | | | |